Arsenigen Saure, better known as Trisenox, is used to treat patients with leukemia that have been unresponsive to other agents. This medication gained approval for use by the FDA as a treatment for leukemia. Being that it is poisonous to the human body, it is one of the highly debatable medications in the field. Arsenigen Saure was first used as a traditional Chinese medicine called Pi Shuang and is still used today to treat cancer patients and other health conditions.
Arsenigen Saure is administered to patients suffering from acute promyelocytic leukemia (APL) and not responding to treatment from the "first-line" agents.
Arsenigen Saure is diluted in intravenous solutions. 100 to 250ml of this medication is put into Dextrose Injection, 0.9% Sodium Chloride Injection, and USP. A single-dose is stored securely and any leftovers from the ampule must be discarded. Arsenigen Saure is administered 1 to 2 hours intravenously but may be extended to 4 hours if there is acute vasomotor reaction observed in the patient.
For bone marrow therapy, Arsenigen Saure is administered at a dose of 0.15 mg per kg weight of the patient daily until bone marrow remission. The total dose given to the patient should not reach 60.
Arsenigen Saure treatment should begin about 3 to 6 weeks after completing the induction therapy. It is administered through IV at 0.15 mg per kg weight of the patient daily for 25 doses in total for 5 weeks, but may fluctuate based on the patient’s condition.
Common side effects include nausea, vomiting, abdominal pains, leukocytosis, fatigue, hyperglycemia, edema, coughing, rash or itching, dyspnea, headaches and dizziness, and some medication-related toxicity (though this is said to be rare). If you experience any of these symptoms, seek immediate medical attention.
No tests have been conducted in regards to the interaction of Arsenigen Saure with other medications. Therefore, it is recommended that the patient first consult a physician and submit to a thorough physical and medical examination to determine the effectiveness and safety of the use of this medication for them. Patients who have adverse allergic reaction to Arsenic Blank should not be treated with this medication.
Patients should be monitored two times a week or more to determine if there are any abnormalities before and after the treatment. This is a high priority for clinically unstable patients.
This medication is in Pregnancy Category D. If you are pregnant or may become pregnant, you should consult your physician before proceeding with the treatment. Nursing mothers should not breastfeed their babies when undergoing Arsenigen Saure treatment to avoid complications within the infant's system. People with renal and hepatic impairment should also consult their physician before proceeding with the treatment.
Arsenigen saure has the following structural formula:
• Chemical IUPAC Name is 2,4,5-trioxa-1,3-diarsabicyclo[1.1.1]pentane
• Molecular weight is 197.841 g/mol
• Arsenigen saure available : 10ml ampules
©2007-2017 Medicalook.com All rights reserved